We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Olympus

Manufactures optical and digital equipment for the healthcare and consumer electronics sectors, including endoscopy a... read more Featured Products: More products

Download Mobile App




Simple Method Developed to Characterize Immune Cells in Tumors

By LabMedica International staff writers
Posted on 27 Jul 2016
Print article
Image: A whole-slide scanner with OlyVIA software (Photo courtesy of Olympus).
Image: A whole-slide scanner with OlyVIA software (Photo courtesy of Olympus).
Despite recent achievements in the development of cancer immunotherapies, only a small group of patients typically respond to them and therefore predictive markers of disease course and response to immunotherapy are urgently needed.

A new method has been developed for analyzing multiple tissue markers using only one slide of a tumor section to better understand immune response occurring locally. The multiplexed immunohistochemical consecutive staining on a single slide (MICSSS) helps characterize human cells involved in immune responses at the tissue site, before and after treatment with immunotherapy.

Scientists at the Icahn School of Medicine at Mount Sinai (New York, NY, USA) and their international colleagues obtained paraffin-embedded human tonsils, ulcerative colitis, non-small cell lung cancer (NSCLC), melanoma, and colorectal tumor samples from their Biorepository tissue bank. The formalin-fixed paraffin embedded (FFPE) were processed for immunohistochemistry (IHC) and images were acquired using an Olympus whole-slide scanner with OlyVIA software (Olympus Life Science, Center Valley, PA, USA) or an Eclipse Ci-E microscope (Nikon Instruments, Melville, NY, USA).

The authors have described a multiplexed chromogenic IHC strategy for high-dimensional tissue analysis that circumvents many of the limitations of regular chromogenic, immunofluorescence, and mass cytometry approaches that could be readily implemented in clinical pathology laboratories. The MICSSS method provides a new powerful tool to map the microenvironment of tissue lesional sites with excellent resolution, in a sample-sparing manner, to monitor immune changes in situ during therapy and help identify prognostic and predictive markers of clinical outcome in patients with cancer and inflammatory diseases.

Sacha Gnjatic, PhD, an Associate Professor and senior co-author said, “Our goal was to get a better understanding of immunologic responses at the tumor site while addressing the need for high-dimensional analysis using as little tissue as possible. We need more comprehensive analyses of the immune microenvironment of tumors, as part of our immune monitoring to inform treatment and predict outcomes for cancer patients.” The study was published on July 14, 2016, in the journal Science Immunology.

Related Links:
Icahn School of Medicine at Mount Sinai
Olympus Life Science
Nikon Instruments
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.